Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 13;5(4):fcad203.
doi: 10.1093/braincomms/fcad203. eCollection 2023.

The Teflon hypothesis

Affiliations

The Teflon hypothesis

Rudy J Castellani et al. Brain Commun. .

Abstract

This scientific commentary refers to 'Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease', by Liu et al. (https://doi.org/10.1093/braincomms/fcad175).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no financial or competing interests.

Comment on

References

    1. Nicoll JAR, Buckland GR, Harrison CH, et al. Persistent neuropathological effects 14 years following amyloid-beta immunization in Alzheimer's disease. Brain. 2019;142(7):2113–2126. - PMC - PubMed
    1. Salloway S, Chalkias S, Barkhof F, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79(1):13–21. - PMC - PubMed
    1. Reish NJ, Jamshidi P, Stamm B, et al. Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N Engl J Med. 2023;388(5):478–479. - PMC - PubMed
    1. Castellani RJ, Shanes ED, McCord M, et al. Neuropathology of anti-amyloid-beta immunotherapy: A case report. J Alzheimers Dis. 2023;93(2):803–813. - PubMed
    1. Liu KY, Villain N, Ayton S, et al. Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer’s disease. Brain Commun. 2023;5(3):fcad175. - PMC - PubMed

LinkOut - more resources